Cell Genesys Inc., of Foster City, Calif., added Peter Working as vice president, research and development.

Cellegy Pharmaceuticals Inc., of South San Francisco, appointed William Schary vice president, regulatory affairs and quality.

Cephalon Inc., of West Chester, Pa., appointed Jess Amchin vice president, medical affairs.

Corgentech Inc., of Palo Alto, Calif., formed a clinical advisory board comprised of Lawrence Cohn, Michael Mack, Mehmet Oz, Randall Wolf, Dennis Bandyk, Alexander Clowes and Michael Conte.

Corvas International Inc., of San Diego, added Laura Hansen as director of investor relations and corporate communications.

Crucell N.V., of Leiden, the Netherlands, appointed Arsia Amir-Aslani vice president, corporate development and strategy.

Cubist Pharmaceuticals Inc., of Cambridge, Mass., added Kerry Flynn as chief intellectual property counsel, Irina Franklin as executive director of business development and Robert Arbeit and Timothy Leach as directors of medical operations.

Devgen, of Ghent, Belgium, appointed Michael Saunders head of metabolic diseases research, Sandra Turconi director of high-throughput screening and assay development, and Jean-Philippe Rocher head of chemistry.

DiaDexus Inc., of Santa Clara, Calif., appointed Patricia Fukami vice president of finance.

DNA Sciences Inc., of Fremont, Calif., appointed Mark Perry and Kenneth Melmon to its board.

Epimmune Inc., of San Diego, appointed Georges Hibon to its board.

Genencor International Inc., of Palo Alto, Calif., named David Thomassen vice president, business development of health care.

Genome Therapeutics Corp., of Waltham, Mass., added Martin Williams as senior vice president, business development and marketing ¿ infectious diseases.

GPC Biotech AG, of Martinsried, Germany, appointed Steven Lazar vice president, worldwide head of intellectual property.

Harvard Bioscience Inc., of Holliston, Mass., promoted Susan Luscinski to chief financial officer.

Hollis-Eden Pharmaceuticals Inc., of San Diego, appointed Richard Trauger director, tumor and vaccine immunology.

No Comments